PTA-Adhoc: Dr. Hönle AG: Reassessment of the business situation and adjustment of the outlook for the 2022/2023 financial year
Public disclosure of inside information according to article 17 MAR
Gilching (pta049/01.06.2023/21:45) - After change of the CEO/CFO the Management Board of Dr. Hönle AG has analysed intensively all segments and business areas of the Hönle Group in recent weeks.
In this context, the Management Board has come to a reassessment of both the situation and the outlook for the Hönle Group in the 2022/2023 financial year. In this context, it decided not to continue the product line of mobile SteriWhite Air disinfection systems due to the lack of prospects of success after corona pandemic has subsided. In connection with the shutdown of the product line, the Management Board has decided, in addition to the already realised partial write-down of the disinfection devices, to completely write-down the inventory of devices and components for these devices (cash neutral). The product line of industrial UVC air disinfection, on the other hand, will be continued.
In addition, the Management Board expects sales and earnings in the current financial year to be below the planned figures, as well as increased personnel expenses at Dr. Hönle AG, which is largely related to the resignation of a former Management Board member.
Overall, the Management Board now expects sales of € 100 million to € 105 million for the Hönle Group in the 2022/2023 financial year. Until now, it had assumed that sales would be lower than in the previous year (€126.5 million).
Furthermore, it expects an operating result (EBIT) without non-recurring effects of €5.5 million to €6.5 million as well as negative non-recurring effects of €13.5 million, which are mainly related to the shutdown of the mobile air disinfection systems product line. Overall, it assumes an operating result (EBIT) of € -7 million to € -8 million. Until now, the Management Board had assumed that the operating result (EBIT) would be significantly higher than the adjusted operating result of the previous year (€8.9 million).
Despite changed forecast, all business areas of the Hönle Group are expected to achieve a positive operating result and a positive operating cash flow overall.
Dr. Hönle AG, headquartered in Gilching, Germany, is a leading supplier of industrial UV technology. With more than 600 employees, Hönle Group develops innovative solutions for various fields of application. One focus of business activities is the development and sale of industrial adhesives and casting compounds. The company also manufactures equipment for the drying of inks and coatings , adhesives and plastics curing, as well as for the disinfection of air, water and surfaces sterilisation, and sunlight simulation. In addition, the corporate group produces UV lamps and quartz glass products for disinfection and drying processes, among others. The Hönle Group supplies technology and global market leaders worldwide and is represented in more than 20 countries by its own companies and partner companies.
emitter: Dr. Hönle AG
address: Nicolaus-Otto-Str. 2, 82205 Gilching
contact person: Peter Weinert
phone: +49 8105 2083 173
ISIN(s): DE0005157101 (share)
stock exchanges: regulated market in Frankfurt; free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf, free market in Hannover; open market in Berlin, Tradegate